---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-151276"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2025-06-27T23:59:59+00:00"
generated_at: "2026-05-18T16:04:10.510712+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics 2025 annual meeting passes director elections, say-on-pay, auditor ratification

## Summary
- Class III directors Katina Dorton, Robert Gould, and Kate Haviland elected with 44.6M, 43.8M, and 33.2M votes for, respectively.
- Non-binding say-on-pay resolution approved with 46.1M votes for (99.8% of votes cast excluding broker non-votes).
- Stockholders selected one year as frequency of future say-on-pay votes (44.9M votes for one year).
- Ernst & Young LLP ratified as independent auditor for FY2025 with 49.5M votes for.

## SEC filing metadata
- accession: 0001193125-25-151276
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2025-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312525151276/0001193125-25-151276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312525151276/d916678d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-151276
- JSON: https://secwatch.observer/filing/0001193125-25-151276.json
- Plain text: https://secwatch.observer/filing/0001193125-25-151276.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.